keyword
MENU ▼
Read by QxMD icon Read
search

falcon trial

keyword
https://www.readbyqxmd.com/read/28422556/the-acute-effects-of-breaking-up-seated-office-work-with-standing-or-light-intensity-walking-on-interstitial-glucose-concentration-a-randomised-crossover-trial
#1
Laura A Brocklebank, Rob C Andrews, Angie Page, Catherine L Falconer, Sam Leary, Ashley Cooper
BACKGROUND: The aim of this randomised, three-period, three-treatment crossover trial was to examine the acute effects of regularly breaking up seated office work with short bouts of standing or light-intensity walking on postprandial interstitial glucose concentration. METHODS: Seventeen middle-aged office workers performed three five-hour trial conditions at their workplace in a random order: 1) uninterrupted sitting; 2) sitting interrupted by two minutes of standing every 20 minutes; and 3) sitting interrupted by two minutes of light-intensity walking every 20 minutes...
April 19, 2017: Journal of Physical Activity & Health
https://www.readbyqxmd.com/read/28414610/clinical-calculator-for-early-mortality-in-metastatic-colorectal-cancer-an-analysis-of-patients-from-28-clinical-trials-in-the-aide-et-recherche-en-canc%C3%A3-rologie-digestive-database
#2
Lindsay A Renfro, Richard M Goldberg, Axel Grothey, Alberto Sobrero, Richard Adams, Matthew T Seymour, Volker Heinemann, Hans-Joachim Schmoll, Jean-Yves Douillard, Herbert Hurwitz, Charles S Fuchs, Eduardo Diaz-Rubio, Rainer Porschen, Christophe Tournigand, Benoist Chibaudel, Paulo M Hoff, Fairooz F Kabbinavar, Alfredo Falcone, Niall C Tebbutt, Cornelis J A Punt, J Randolph Hecht, John Souglakos, Carsten Bokemeyer, Eric Van Cutsem, Leonard Saltz, Aimery de Gramont, Daniel J Sargent
Purpose Factors contributing to early mortality after initiation of treatment of metastatic colorectal cancer are poorly understood. Materials and Methods Data from 22,654 patients enrolled in 28 randomized phase III trials contained in the ARCAD (Aide et Recherche en Cancérologie Digestive) database were pooled. Multivariable logistic regression models for 30-, 60-, and 90-day mortality were constructed, including clinically and statistically significant patient and disease factors and interaction terms. A calculator (nomogram) for 90-day mortality was developed and validated internally using bootstrapping methods and externally using a 10% random holdout sample from each trial...
April 17, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28369940/single-nucleotide-polymorphisms-in-the-igf-irs-pathway-are-associated-with-outcome-in-mcrc-patients-enrolled-in-the-fire-3-trial
#3
Marta Schirripa, Wu Zhang, Volker Heinemann, Shu Cao, Satoshi Okazaki, Dongyun Yang, Fotios Loupakis, Martin D Berger, Yan Ning, Yuji Miyamoto, Mitsukuni Suenaga, Roel F Gopez, Jordan D West, Diana Hanna, Afsaneh Barzi, Alfredo Falcone, Sebastian Stintzing, Heinz-Josef Lenz
The Insulin-like growth factor (IGF)/IGF-receptor pathway with its scaffolding proteins Insulin Receptor Substrate (IRS)1 and IRS2 are crucial regulators of metabolism and progression in metastatic colorectal cancer (mCRC). The goal of the study was the identification of predictive and prognostic markers among IRS1, IRS2, IGF1 and IGF-1R SNPs in mCRC patients enrolled in the FIRE-3 trial. Four SNPs of IRS (IRS1 rs1801278, rs1801123; IRS2 rs1805097, rs2289046) and 4 SNPs of IGF1-IGFR1 (rs6214, rs6220, rs2946834, rs2016347) were analyzed by PCR/direct-sequencing in the FIRE-3 trial...
April 1, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28347919/autophagy-related-polymorphisms-predict-hypertension-in-patients-with-metastatic-colorectal-cancer-treated-with-folfiri-and-bevacizumab-results-from-tribe-and-fire-3-trials
#4
Martin D Berger, Shinichi Yamauchi, Shu Cao, Diana L Hanna, Yu Sunakawa, Marta Schirripa, Satoshi Matsusaka, Dongyun Yang, Susan Groshen, Wu Zhang, Yan Ning, Satoshi Okazaki, Yuji Miyamoto, Mitsukuni Suenaga, Sara Lonardi, Chiara Cremolini, Alfredo Falcone, Volker Heinemann, Fotios Loupakis, Sebastian Stintzing, Heinz-Josef Lenz
PURPOSE: The most frequent bevacizumab-related side-effects are hypertension, proteinuria, bleeding and thromboembolism. To date, there is no biomarker that predicts anti-VEGF-associated toxicity. As autophagy inhibits angiogenesis, we hypothesised that single-nucleotide polymorphisms (SNPs) within autophagy-related genes may predict bevacizumab-mediated toxicity in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: Patients with mCRC treated with first-line FOLFIRI and bevacizumab in two phase III randomised trials, namely the TRIBE trial (n = 219, discovery cohort) and the FIRE-3 trial (n = 234, validation cohort) were included in this study...
March 24, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28295794/alcohol-and-disadvantaged-men-a-feasibility-trial-of-an-intervention-delivered-by-mobile-phone
#5
Iain K Crombie, Linda Irvine, Donald W Falconer, Brian Williams, Ian W Ricketts, Claire Jones, Gerry Humphris, John Norrie, Peter Slane, Peter Rice
INTRODUCTION AND AIMS: Disadvantaged men suffer substantial harm from heavy drinking. This feasibility study developed and evaluated the methods for a trial of a brief intervention delivered by text messages to disadvantaged men. It aimed to test the methods for recruitment and retention, to monitor engagement with the intervention and assess the overall acceptability of study methods. DESIGN AND METHODS: Disadvantaged men aged 25-44 years who had ≥2 episodes of binge drinking (≥8 units in one session) in the preceding month were recruited...
March 13, 2017: Drug and Alcohol Review
https://www.readbyqxmd.com/read/28238489/laparoscopy-vs-robotic-surgery-for-endometriosis-larose-a-multicenter-randomized-controlled-trial
#6
Enrique Soto, Thanh Ha Luu, Xiaobo Liu, Javier F Magrina, Megan N Wasson, Jon I Einarsson, Sarah L Cohen, Tommaso Falcone
OBJECTIVE: To determine whether the use of the robot for surgical treatment of endometriosis is better than traditional laparoscopy in terms of operative length, perioperative parameters, and quality of life outcomes. DESIGN: Multicenter, randomized clinical trial. SETTING: University teaching hospitals. PATIENT(S): Women aged >18 years with suspected endometriosis who elected to undergo surgical management. INTERVENTION(S): Randomization to conventional or robot-assisted laparoscopic removal of endometriosis...
April 2017: Fertility and Sterility
https://www.readbyqxmd.com/read/28081548/serum-ldh-predicts-benefit-from-bevacizumab-beyond-progression-in-metastatic-colorectal-cancer
#7
Federica Marmorino, Lisa Salvatore, Cecilia Barbara, Giacomo Allegrini, Lorenzo Antonuzzo, Gianluca Masi, Fotios Loupakis, Beatrice Borelli, Silvana Chiara, Maria Chiara Banzi, Emanuela Miraglio, Domenico Amoroso, Francesco Dargenio, Andrea Bonetti, Angelo Martignetti, Myriam Paris, Daniela Tomcikova, Luca Boni, Alfredo Falcone, Chiara Cremolini
BACKGROUND: Different antiangiogenics are currently indicated in the second-line treatment of metastatic colorectal cancer (mCRC), following a first-line bevacizumab-containing treatment. The magnitude of benefit is limited, but no predictors of benefit have been identified. METHODS: A total of 184 mCRC patients progressing to a first-line bevacizumab-containing treatment were randomised in the BEBYP study to continue or not the antiangiogenic in combination with a second-line chemotherapy...
January 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28008174/autologous-transplant-vs-oral-chemotherapy-and-lenalidomide-in-newly-diagnosed-young-myeloma-patients-a-pooled-analysis
#8
F Gay, S Oliva, M T Petrucci, V Montefusco, C Conticello, P Musto, L Catalano, A Evangelista, S Spada, P Campbell, R Ria, M Salvini, M Offidani, A M Carella, P Omedé, A M Liberati, R Troia, A M Cafro, A Malfitano, A P Falcone, T Caravita, F Patriarca, A Nagler, A Spencer, R Hajek, A Palumbo, M Boccadoro
In newly diagnosed myeloma patients, upfront autologous transplant (ASCT) prolongs progression-free survival 1 (PFS1) compared with chemotherapy plus lenalidomide (CC+R). Salvage ASCT at first relapse may still effectively rescue patients who did not receive upfront ASCT. To evaluate the long-term benefit of upfront ASCT vs CC+R and the impact of salvage ASCT in patients who received upfront CC+R, we conducted a pooled analysis of 2 phase III trials (RV-MM-209 and EMN-441). Primary endpoints were PFS1, progression-free survival 2 (PFS2), overall survival (OS)...
January 24, 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/27986363/efficacy-of-folfoxiri-plus-bevacizumab-in-liver-limited-metastatic-colorectal-cancer-a-pooled-analysis-of-clinical-studies-by-gruppo-oncologico-del-nord-ovest
#9
Chiara Cremolini, Mariaelena Casagrande, Fotios Loupakis, Giuseppe Aprile, Francesca Bergamo, Gianluca Masi, Roberto Moretto R, Filippo Pietrantonio, Federica Marmorino, Gemma Zucchelli, Gianluca Tomasello, Giuseppe Tonini, Giacomo Allegrini, Cristina Granetto, Laura Ferrari, Lucio Urbani, Umberto Cillo, Pierluigi Pilati, Elisa Sensi, Alessio Pellegrinelli, Massimo Milione, Gabriella Fontanini, Alfredo Falcone
Secondary resection is a chance of cure for a subgroup of metastatic colorectal cancer (mCRC) patients with unresectable liver-limited disease. Medical treatment has a dual goal: to induce tumour shrinkage and to prevent disease relapse. The aims of the present analysis were to assess the efficacy of FOLFOXIRI plus bevacizumab in this setting, and to investigate whether this regimen could revert the poor prognosis of high-risk patients defined by clinical and molecular factors. We performed a pooled analysis of patients with unresectable and liver-limited mCRC, treated with first-line FOLFOXIRI plus bevacizumab in three prospective clinical trials by Gruppo Oncologico del Nord Ovest...
March 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/27943285/annual-research-review-digital-health-interventions-for-children-and-young-people-with-mental-health-problems-a-systematic-and-meta-review
#10
REVIEW
Chris Hollis, Caroline J Falconer, Jennifer L Martin, Craig Whittington, Sarah Stockton, Cris Glazebrook, E Bethan Davies
BACKGROUND: Digital health interventions (DHIs), including computer-assisted therapy, smartphone apps and wearable technologies, are heralded as having enormous potential to improve uptake and accessibility, efficiency, clinical effectiveness and personalisation of mental health interventions. It is generally assumed that DHIs will be preferred by children and young people (CYP) given their ubiquitous digital activity. However, it remains uncertain whether: DHIs for CYP are clinically and cost-effective, CYP prefer DHIs to traditional services, DHIs widen access and how they should be evaluated and adopted by mental health services...
April 2017: Journal of Child Psychology and Psychiatry, and Allied Disciplines
https://www.readbyqxmd.com/read/27908454/fulvestrant-500-mg-versus-anastrozole-1-mg-for-hormone-receptor-positive-advanced-breast-cancer-falcon-an-international-randomised-double-blind-phase-3-trial
#11
John F R Robertson, Igor M Bondarenko, Ekaterina Trishkina, Mikhail Dvorkin, Lawrence Panasci, Alexey Manikhas, Yaroslav Shparyk, Servando Cardona-Huerta, Kwok-Leung Cheung, Manuel Jesus Philco-Salas, Manuel Ruiz-Borrego, Zhimin Shao, Shinzaburo Noguchi, Jacqui Rowbottom, Mary Stuart, Lynda M Grinsted, Mehdi Fazal, Matthew J Ellis
BACKGROUND: Aromatase inhibitors are a standard of care for hormone receptor-positive locally advanced or metastatic breast cancer. We investigated whether the selective oestrogen receptor degrader fulvestrant could improve progression-free survival compared with anastrozole in postmenopausal patients who had not received previous endocrine therapy. METHODS: In this phase 3, randomised, double-blind trial, we recruited eligible patients with histologically confirmed oestrogen receptor-positive or progesterone receptor-positive, or both, locally advanced or metastatic breast cancer from 113 academic hospitals and community centres in 20 countries...
December 17, 2016: Lancet
https://www.readbyqxmd.com/read/27886643/cardiac-safety-of-adjuvant-non-pegylated-liposomal-doxorubicin-combined-with-cyclophosphamide-and-followed-by-paclitaxel-in-older-breast-cancer-patients
#12
Luigi Coltelli, Andrea Fontana, Sara Lucchesi, Laura Ginocchi, Guido Bocci, Mario Filidei, Marco Scalese, Giada Arrighi, Chiara Finale, Lorenzo Marcucci, Orlando Goletti, Barbara Salvadori, Ilaria Ferrarini, Eleonora Bona, Alfredo Falcone, Giacomo Allegrini
PURPOSE: To investigate the cardiac safety of adjuvant Non-Pegylated Liposomal Doxorubicin (NPL-DOX) combined to Cyclophosphamide (CTX) and followed by weekly Paclitaxel, in older patients (≥65 years) with diagnosis of high risk breast cancer. The main end point of this prospective study was the detection of early episodes of symptomatic congestive heart failure (CHF). METHODS: The cardiac function was evaluated by left ventricular ejection fraction (LVEF) measurements with repeated echocardiograms, performed 2 weeks before the beginning of chemotherapy and every 6 months, until 30 months after the study entry; then yearly for at least 5 years...
February 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/27864220/estimating-12-week-death-probability-in-patients-with-refractory-metastatic-colorectal-cancer-the-colon-life-nomogram
#13
F Pietrantonio, R Miceli, L Rimassa, S Lonardi, G Aprile, A Mennitto, F Marmorino, S Bozzarelli, L Antonuzzo, E Tamburini, F Morano, D Rossini, F Battaglin, M Baretti, R Berenato, V Formica, S Mosconi, F Petrelli, M Ghidini, F Loupakis, D Spada, S Cinieri, G Beretta, A Falcone, F de Braud, C Cremolini
Background: Regorafenib and TAS-102 have recently demonstrated statistically significant survival gains in patients with refractory metastatic colorectal cancer (mCRC). Life expectancy ≥12 weeks was an inclusion criterion in registrative trials, and the identification of proper clinical selection tools for the daily use of these drugs in heavily pre-treated patients is needed to improve the cost-benefit ratio. We aimed at building a nomogram able to predict death probability within 12 weeks from the date of assessment of refractory mCRC...
March 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27861516/the-mcme-project-a-randomized-controlled-trial-of-an-sms-based-continuing-medical-education-intervention-for-improving-medical-knowledge-among-vietnamese-community-based-physicians-assistants
#14
Christopher J Gill, Bao Le Ngoc, Nafisa Halim, Ha Nguyen Viet, Anna Larson Williams, Tan Nguyen Van, Marion McNabb, Lien Tran Thi Ngoc, Ariel Falconer, Hai An Phan Ha, Julia Rohr, Hai Hoang, James Michiel, Tam Nguyen Thi Thanh, Liat Bird, Hoang Pham Vu, Mahlet Yeshitla, Nhu Ha Van, Lora Sabin
BACKGROUND: Community health workers (CHWs) provide critical services to underserved populations in low and middle-income countries, but maintaining CHW's clinical knowledge through formal continuing medical education (CME) activities is challenging and rarely occurs. We tested whether a Short Message Service (SMS)-based mobile CME (mCME) intervention could improve medical knowledge among a cadre of Vietnamese CHWs (Community Based Physician's Assistants-CBPAs) who are the leading providers of primary medical care for rural underserved populations...
2016: PloS One
https://www.readbyqxmd.com/read/27857020/surrogate-endpoints-in-second-line-trials-of-targeted-agents-in-metastatic-colorectal-cancer-a-literature-based-systematic-review-and-meta-analysis
#15
Chiara Cremolini, Carlotta Antoniotti, Filippo Pietrantonio, Rosa Berenato, Marco Tampellini, Chiara Baratelli, Lisa Salvatore, Federica Marmorino, Beatrice Borelli, Federico Nichetti, Paolo Bironzo, Cristina Sonetto, Maria Di Bartolomeo, Filippo de Braud, Fotios Loupakis, Alfredo Falcone, Massimo Di Maio
Purpose: To evaluate progression-free survival (PFS) and objective response rate (ORR) as surrogate endpoints of overall survival (OS) in modern clinical trials investigating the efficacy of targeted agents in the second-line treatment of metastatic colorectal cancer (mCRC). Materials and Methods: A systematic search of literature pertaining to randomized phase II and III trials evaluating targeted agents as second-line treatments for mCRC was performed. The strength of the correlation between both PFS and ORR and OS was assessed based on the Pearson's correlation coefficient (R) and the coefficient of determination (R2)...
November 15, 2016: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/27788564/does-positron-emission-tomography-computed-tomography-change-management-in-colorectal-cancer
#16
Rachel Falconer, Saxon Connor, Adrian Balasingam, Tim Eglinton
BACKGROUND: Positron emission tomography/computed tomography (PET/CT) is used pre-operatively in patients with metastatic or recurrent colorectal cancer to identify those who have potentially curative disease. However, a recent randomized trial questioned the added benefit of PET/CT over conventional imaging in patients with liver metastases. The aim of this study was to determine the proportion of patients with colorectal cancer in whom PET/CT altered surgical management, in a single tertiary centre...
October 27, 2016: ANZ Journal of Surgery
https://www.readbyqxmd.com/read/27743922/prognosis-of-patients-with-peritoneal-metastatic-colorectal-cancer-given-systemic-therapy-an-analysis-of-individual-patient-data-from-prospective-randomised-trials-from-the-analysis-and-research-in-cancers-of-the-digestive-system-arcad-database
#17
Jan Franko, Qian Shi, Jeffrey P Meyers, Timothy S Maughan, Richard A Adams, Matthew T Seymour, Leonard Saltz, Cornelis J A Punt, Miriam Koopman, Christophe Tournigand, Niall C Tebbutt, Eduardo Diaz-Rubio, John Souglakos, Alfredo Falcone, Benoist Chibaudel, Volker Heinemann, Joseph Moen, Aimery De Gramont, Daniel J Sargent, Axel Grothey
BACKGROUND: Patients with peritoneal metastatic colorectal cancer have reduced overall survival compared with patients with metastatic colorectal cancer without peritoneal involvement. Here we further investigated the effect of the number and location of metastases in patients receiving first-line systemic chemotherapy. METHODS: We analysed individual patient data for previously untreated patients enrolled in 14 phase 3 randomised trials done between 1997 and 2008...
December 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27703757/embodying-self-compassion-within-virtual-reality-and-its-effects-on-patients-with-depression
#18
Caroline J Falconer, Aitor Rovira, John A King, Paul Gilbert, Angus Antley, Pasco Fearon, Neil Ralph, Mel Slater, Chris R Brewin
BACKGROUND: Self-criticism is a ubiquitous feature of psychopathology and can be combatted by increasing levels of self-compassion. However, some patients are resistant to self-compassion. AIMS: To investigate whether the effects of self-identification with virtual bodies within immersive virtual reality could be exploited to increase self-compassion in patients with depression. METHOD: We developed an 8-minute scenario in which 15 patients practised delivering compassion in one virtual body and then experienced receiving it from themselves in another virtual body...
January 2016: BJPsych Open
https://www.readbyqxmd.com/read/27660192/adjuvant-capecitabine-plus-bevacizumab-versus-capecitabine-alone-in-patients-with-colorectal-cancer-quasar-2-an-open-label-randomised-phase-3-trial
#19
Rachel S Kerr, Sharon Love, Eva Segelov, Elaine Johnstone, Beverly Falcon, Peter Hewett, Andrew Weaver, David Church, Claire Scudder, Sarah Pearson, Patrick Julier, Francesco Pezzella, Ian Tomlinson, Enric Domingo, David J Kerr
BACKGROUND: Antiangiogenic agents have established efficacy in the treatment of metastatic colorectal cancer. We investigated whether bevacizumab could improve disease-free survival in the adjuvant setting after resection of the primary tumour. METHODS: For the open-label, randomised, controlled QUASAR 2 trial, which was done at 170 hospitals in seven countries, we recruited patients aged 18 years or older with WHO performance status scores of 0 or 1 who had undergone potentially curative surgery for histologically proven stage III or high-risk stage II colorectal cancer...
November 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27656206/treatment-with-antiangiogenic-drugs-in-multiple-lines-in-patients-with-metastatic-colorectal-cancer-meta-analysis-of-randomized-trials
#20
REVIEW
R-D Hofheinz, U Ronellenfitsch, S Kubicka, A Falcone, I Burkholder, U T Hacker
Background. In metastatic colorectal cancer (mCRC), continuing antiangiogenic drugs beyond progression might provide clinical benefit. We synthesized the available evidence in a meta-analysis. Patients and Methods. We conducted a meta-analysis of studies investigating the use of antiangiogenic drugs beyond progression. Eligible studies were randomized phase II/III trials. Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints were the impact of continuing antiangiogenic drugs (i) in subgroups, (ii) in different types of compounds targeting the VEGF-axis (monoclonal antibodies versus tyrosine kinase inhibitors), and (iii) on remission rates and prevention of progression...
2016: Gastroenterology Research and Practice
keyword
keyword
120390
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"